Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05YLP
|
|||
| Former ID |
DIB001329
|
|||
| Drug Name |
SP-333
|
|||
| Synonyms |
Guanylate cyclase-C receptor agonist (peptide, UC), Synergy Pharmaceuticals; Guanylate cyclase-C receptor analog (peptide, UC), Synergy Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | |
| Company |
Synergy Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Guanylyl cyclase C (GUCY2C) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01983306) Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.